Laxxon Medical Unveils Oral GLP-1 Agonist at BIO Europe 2024

Laxxon Medical, a US-based pharma-tech company, will present its innovative LXM.2 asset at the 2024 BIO-Europe Convention in Stockholm. The LXM.2 is a 3D printed oral GLP-1 agonist designed for weight loss, offering a non-invasive once-a-day alternative to traditional injectable treatments. By utilizing enterically coated micro-tablets, Laxxon aims to enhance patient compliance, especially in pediatric groups.

The active ingredient in LXM.2 is FDA-approved for adult and pediatric weight management, and the product is eligible for the FDA’s 505(b)2 development pathway. With its proprietary SPID® technology, Laxxon ensures stable core production with permeation enhancers, maximizing bioavailability. This development promises to shift the current reliance on injectable GLP-1 formulations.

At the convention, Laxxon seeks partnerships for further development of LXM.2. The company's presentation highlights potentially transformative impacts on the pharmaceutical landscape.